Conditions: Neoplasms
Keywords: Phase 1 Dose Finding Solid Tumors Tumors PF-05212384
Enrollment: 78
Healthy volunteers: no

Brief summary:
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.

Detailed description:

Arms:
arm 1: PF-05212384 (also known as PKI-587)

Interventions: intervention 1: PF-05212384 (also known as PKI-587)
Intervention descriptions: intervention 1: Intravenous dosing once weekly infusion

Protocol document: